| Assessment Status | NCPE Assessment process complete |
| HTA ID | - |
| Drug | Cysteamine bitartrate delayed-release |
| Brand | Procysbi® |
| Indication | For the treatment of proven nephropathic cystinosis. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2015 |
| Rapid review completed | 15/12/2015 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price |
| Full pharmacoeconomic assessment commissioned by HSE | 23/12/2015 |
| Pre-submission consultation with Applicant | 22/05/2017 |
| Full submission received from Applicant | 13/07/2017 |
| Preliminary review sent to Applicant | 22/08/2017 |
| NCPE assessment re-commenced | 29/08/2017 |
| Factual accuracy sent to Applicant | 17/10/2017 |
| NCPE assessment re-commenced | 15/11/2017 |
| NCPE assessment completed | 15/11/2017 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The HSE has approved reimbursement following confidential price negotiations; July 2019
